Physician Assistant, Medical · Eureka, CA
NPI
1538398870
Since 2009
Specialty
Physician Assistant, Medical
Code 363AM0700X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
525 2nd St Ste 203
Eureka, CA, 95501
Phone (707) 444-1331
Groups this clinician bills Medicare through
Medicare paid, 2024
$291K
8,344 services
Medicare patients, 2024
1,587
Average age 74
Drug cost, 2024
$2.7M
1,581 prescriptions
Company payments, 2025
$2,262
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mandi L Battles was code 17003 (destruction skin lesion), 3,460 times for 622 patients. In total Mandi L Battles billed 8,344 services in 64 codes, and Medicare paid $291K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-09-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 3,460 | 622 | $4.32 | $15K |
| 99213 Office E&M - Established | Office | 1,325 | 1,018 | $50.67 | $67K |
| 17000 Destruction Skin Lesion | Office | 907 | 793 | $30.09 | $27K |
| 17110 Destruction Skin Lesion | Office | 634 | 574 | $64.49 | $41K |
| 99214 Office E&M - Established | Office | 593 | 442 | $74.12 | $44K |
| 99203 Office E&M - New | Office | 216 | 216 | $51.10 | $11K |
| 17004 Destruction Skin Lesion | Office | 189 | 153 | $97.95 | $19K |
| 11102 Skin Biopsy | Office | 160 | 149 | $50.14 | $8,023 |
| 17262 Destruction Skin Lesion | Office | 85 | 60 | $102.38 | $8,702 |
| 17111 Destruction Skin Lesion | Office | 81 | 73 | $77.47 | $6,275 |
| 99212 Office E&M - Established | Office | 79 | 76 | $31.77 | $2,509 |
| 17281 Destruction Skin Lesion | Office | 66 | 62 | $111.00 | $7,326 |
| 11200 Removal or Shaving of Skin Growth | Office | 58 | 57 | $37.52 | $2,176 |
| 99204 Office E&M - New | Office | 56 | 56 | $78.42 | $4,392 |
| 17261 Destruction Skin Lesion | Office | 55 | 45 | $78.86 | $4,337 |
By year: 2023 $39K for 989 services; 2024 $291K for 8,344 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mandi L Battles prescribed most often to Medicare patients was Dutasteride, with 129 prescriptions and refills. In total Mandi L Battles wrote 1,581 Medicare prescriptions that cost $2.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Dutasteride Generic | 129 | 293 | 45 | $3,905 |
| Ketoconazole Generic | 106 | 117 | 59 | $2,365 |
| Mometasone Furoate Generic | 97 | 103 | 89 | $1,672 |
| Dupixent Pen Dupilumab | 96 | 96 | 18 | $362K |
| Terbinafine Hcl Generic | 93 | 153 | 36 | $781 |
| Doxycycline Monohydrate Generic | 89 | 102 | 41 | $1,947 |
| Imiquimod Generic | 87 | 105 | 74 | $2,578 |
| Doxycycline Hyclate Generic | 55 | 66 | 16 | $1,502 |
| Metronidazole Generic | 44 | 53 | 32 | $3,087 |
| Skyrizi Pen Risankizumab-Rzaa | 32 | 90 | Under 11 | $664K |
| Triamcinolone Acetonide Generic | 31 | 42 | 25 | $355 |
| Rosuvastatin Calcium Generic | 31 | 77 | 13 | $1,018 |
| Tacrolimus Generic | 28 | 30 | 20 | $2,811 |
| Gentamicin Sulfate Generic | 25 | 25 | 24 | $726 |
| Fluconazole Generic | 25 | 29 | 13 | $225 |
Brand drugs: - claims; generic drugs: 1,189 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mandi L Battles $2,262 ($2,262 in general payments such as food, travel and fees) from 14 companies. The largest payer was Abbvie Inc. with $512.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 20 | $512 |
| Lilly USA, LLC LLY | 15 | $357 |
| Janssen Biotech, Inc. JNJ | 9 | $336 |
| Galderma Laboratories, L.P. GALD.SW | 10 | $187 |
| UCB, Inc. UCB.BR | 6 | $157 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | 7 | $138 |
| Arcutis Biotherapeutics, Inc. ARQT | 5 | $109 |
| Incyte Corporation INCY | 5 | $105 |
| Regeneron Healthcare Solutions, Inc. REGN | 3 | $93.53 |
| Genzyme Corporation SNY | 3 | $83.53 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.